Histone deacetylase inhibitor valproic acid enhances the cytokine-induced expansion of human hematopoietic stem cells.

Ex vivo amplification of human hematopoietic stem cells (HSC) without loss of their self-renewing potential represents an important target for transplantation, gene and cellular therapies. Valproic acid is a safe and widely used neurologic agent that acts as a potent inhibitor of histone deacetylase activities. Here, we show that valproic acid addition to liquid cultures of human CD34+ cells isolated from cord blood, mobilized peripheral blood, and bone marrow strongly enhances the ex vivo expansion potential of different cytokine cocktails as shown by morphologic, cytochemical, immunophenotypical, clonogenic, and gene expression analyses. Notably, valproic acid highly preserves the CD34 positivity after 1 week (range, 40-89%) or 3 weeks (range, 21-52%) amplification cultures with two (Flt3L + thrombopoietin) or four cytokines (Flt3L + thrombopoietin + stem cell factor + interleukin 3). Moreover, valproic acid treatment increases histone H4 acetylation levels at specific regulatory sites on HOXB4, a transcription factor gene with a key role in the regulation of HSC self-renewal and AC133, a recognized marker gene for stem cell populations. Overall, our results relate the changes induced by valproic acid on chromatin accessibility with the enhancement of the cytokine effect on the maintenance and expansion of a primitive hematopoietic stem cell population. These findings underscore the potentiality of novel epigenetic approaches to modify HSC fate in vitro.

[1]  U. Germing,et al.  Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. , 2004, Blood.

[2]  N. Mahmud,et al.  Modification of hematopoietic stem cell fate by 5aza 2'deoxycytidine and trichostatin A. , 2004, Blood.

[3]  Peter A. Jones,et al.  Epigenetics in human disease and prospects for epigenetic therapy , 2004, Nature.

[4]  S. Rafii,et al.  Alternative promoters regulate transcription of the gene that encodes stem cell surface protein AC133. , 2004, Blood.

[5]  Irving L Weissman,et al.  Biology of hematopoietic stem cells and progenitors: implications for clinical application. , 2003, Annual review of immunology.

[6]  J. Krosl,et al.  In vitro expansion of hematopoietic stem cells by recombinant TAT-HOXB4 protein , 2003, Nature Medicine.

[7]  P. Romeo,et al.  Ex vivo expansion of human hematopoietic stem cells by direct delivery of the HOXB4 homeoprotein , 2003, Nature Medicine.

[8]  Jiang Zhu,et al.  NF-Y cooperates with USF1/2 to induce the hematopoietic expression of HOXB4. , 2003, Blood.

[9]  D. Moazed,et al.  Heterochromatin and Epigenetic Control of Gene Expression , 2003, Science.

[10]  Ricky W Johnstone,et al.  Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? , 2003, Cancer cell.

[11]  Ping Zhu,et al.  The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2 , 2003, The EMBO journal.

[12]  S. Weissman,et al.  Marrow Stem Cells Shift Gene Expression and Engraftment Phenotype with Cell Cycle Transit , 2003, The Journal of experimental medicine.

[13]  I. Weissman,et al.  A role for Wnt signalling in self-renewal of haematopoietic stem cells , 2003, Nature.

[14]  G. Sauvageau,et al.  Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells , 2003, Nature.

[15]  Irving L. Weissman,et al.  Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells , 2003, Nature.

[16]  J. Dick,et al.  Stem cells: Self-renewal writ in blood , 2003, Nature.

[17]  A. Bird,et al.  Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals , 2003, Nature Genetics.

[18]  M. Miñana,et al.  CD34+CD38– is a good predictive marker of cloning ability and expansion potential of CD34+ cord blood cells , 2003, Transfusion.

[19]  H. Lazarus,et al.  Clinical application of hematopoietic progenitor cell expansion: current status and future prospects , 2003, Bone Marrow Transplantation.

[20]  P. Quesenberry,et al.  The chiaroscuro stem cell: a unified stem cell theory. , 2002, Blood.

[21]  J Wagner,et al.  Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. , 2002, Blood.

[22]  Zhigang Gao,et al.  Human stem-progenitor cells from neonatal cord blood have greater hematopoietic expansion capacity than those from mobilized adult blood. , 2002, Experimental hematology.

[23]  G. Sauvageau,et al.  HOXB4-Induced Expansion of Adult Hematopoietic Stem Cells Ex Vivo , 2002, Cell.

[24]  Ping Zhu,et al.  Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells , 2001, The EMBO journal.

[25]  P. Bolufer,et al.  Standardized, unrelated donor cord blood transplantation in adults with hematologic malignancies. , 2001, Blood.

[26]  J. Wagner,et al.  Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. , 2001, The New England journal of medicine.

[27]  Pier Giuseppe Pelicci,et al.  Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias? , 2001, Oncogene.

[28]  F. Pflumio,et al.  In vitro and in vivo evidence for the long-term multilineage (myeloid, B, NK, and T) reconstitution capacity of ex vivo expanded human CD34(+) cord blood cells. , 2000, Experimental hematology.

[29]  T. Kadesch,et al.  Hematopoietic Expression of Hoxb4 Is Regulated in Normal and Leukemic Stem Cells through Transcriptional Activation of the Hoxb4 Promoter by Upstream Stimulating Factor (Usf)-1 and Usf-2 , 2000, The Journal of experimental medicine.

[30]  P. Marks,et al.  Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. , 2000, Journal of the National Cancer Institute.

[31]  T. Di Pucchio,et al.  Flt3L induces the ex‐vivo amplification of umbilical cord blood committed progenitors and early stem cells in short‐term cultures , 1999, British journal of haematology.

[32]  W. Piacibello,et al.  Engraftment in nonobese diabetic severe combined immunodeficient mice of human CD34(+) cord blood cells after ex vivo expansion: evidence for the amplification and self-renewal of repopulating stem cells. , 1999, Blood.

[33]  J. Segovia,et al.  Delayed Engraftment of Nonobese Diabetic/Severe Combined Immunodeficient Mice Transplanted With Ex Vivo–Expanded Human CD34+ Cord Blood Cells , 1999 .

[34]  C. Heyworth,et al.  Differential Response of CD34+ Cells Isolated from Cord Blood and Bone Marrow to MIP‐1α and the Expression of MIP‐1α Receptors on These Immature Cells , 1998 .

[35]  J. Wuu,et al.  The Fluctuating Phenotype of the Lymphohematopoietic Stem Cell with Cell Cycle Transit , 1998, The Journal of experimental medicine.

[36]  J. Kearney,et al.  AC133, a novel marker for human hematopoietic stem and progenitor cells. , 1997, Blood.

[37]  C. Eaves,et al.  Expansion in vitro of transplantable human cord blood stem cells demonstrated using a quantitative assay of their lympho-myeloid repopulating activity in nonobese diabetic-scid/scid mice. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[38]  C. Chastang,et al.  Outcome of cord-blood transplantation from related and unrelated donors , 1997 .

[39]  W. Piacibello,et al.  Extensive amplification and self-renewal of human primitive hematopoietic stem cells from cord blood. , 1997, Blood.

[40]  M. Ogawa,et al.  In vitro expansion of hematopoietic progenitors and maintenance of stem cells: comparison between FLT3/FLK-2 ligand and KIT ligand. , 1997, Blood.

[41]  C. Hannum,et al.  FLT3 ligand preserves the ability of human CD34+ progenitors to sustain long-term hematopoiesis in immune-deficient mice after ex vivo retroviral-mediated transduction. , 1997, Blood.

[42]  J M Piret,et al.  Differential cytokine effects on primitive (CD34+CD38-) human hematopoietic cells: novel responses to Flt3-ligand and thrombopoietin , 1996, The Journal of experimental medicine.

[43]  C. Hannum,et al.  Flt3 ligand induces proliferation of quiescent human bone marrow CD34+CD38- cells and maintains progenitor cells in vitro. , 1996, Blood.

[44]  K. Cornetta,et al.  Ex vivo expansion of murine hematopoietic progenitor cells generates classes of expanded cells possessing different levels of bone marrow repopulating potential. , 1996, Experimental hematology.

[45]  J. Adamson,et al.  Processing and cryopreservation of placental/umbilical cord blood for unrelated bone marrow reconstitution. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[46]  U. Thorsteinsdóttir,et al.  Overexpression of HOXB4 in hematopoietic cells causes the selective expansion of more primitive populations in vitro and in vivo. , 1995, Genes & development.

[47]  P. Barretti,et al.  Transfusion , 1889, The Hospital.

[48]  Z. Han,et al.  Short-term ex vivo expansion sustains the homing-related properties of umbilical cord blood hematopoietic stem and progenitor cells. , 2004, Haematologica.

[49]  T. Reya.  Regulation of hematopoietic stem cell self-renewal. , 2003, Recent progress in hormone research.

[50]  P G Pelicci,et al.  Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. , 2001, Cancer research.

[51]  D. Bryder,et al.  Interleukin-3 supports expansion of long-term multilineage repopulating activity after multiple stem cell divisions in vitro. , 2000, Blood.

[52]  J. Segovia,et al.  Delayed engraftment of nonobese diabetic/severe combined immunodeficient mice transplanted with ex vivo-expanded human CD34(+) cord blood cells. , 1999, Blood.

[53]  C. Chastang,et al.  Outcome of cord-blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. , 1997, The New England journal of medicine.